New Pharmacological Treatment of Obesity: The Role of GLP-1 and Dual GIP/GLP-1 Receptor Agonists

Öz

Obesity is a chronic, relapsing disease associated with substantial cardiometabolic, mechanical, hepatic, renal, and psychosocial complications. Although lifestyle intervention remains the foundation of treatment, pharmacotherapy is indicated when lifestyle measures alone do not provide sufficient benefit, particularly in individuals with a body mass index of at least 30 kg/m², or at least 27 kg/m² in the presence of obesity-related complications. Incretin-based therapies have transformed obesity management by producing weight loss that approaches or exceeds that achieved with some bariatric procedures. Liraglutide, once-weekly semaglutide and tirzepatide achieve weight reduction and they have shown benefits besides weight lowering effects. Treatment selection should be individualized according to expected weight loss, obesity-related complications, tolerability, contraindications, route of administration, access, cost, and patient preference. Because discontinuation is commonly followed by weight regain and reversal of metabolic improvements, incretin-based pharmacotherapy should be regarded as long-term disease-modifying treatment. Current evidence supports a complication-centered approach in which efficacy is assessed through weight, waist circumference, glycemic control, cardiovascular risk factors, functional status, and patient-reported outcomes over time.

Anahtar Kelimeler

• Obesity
• incretin-based therapy
• GLP-1 receptor agonists
• semaglutide
• tirzepatide

Obezitenin Yeni Farmakolojik Tedavisi: GLP-1 ve İkili GIP/GLP-1 Reseptör Agonistlerinin Rolü

Öz

Obezite; önemli kardiyometabolik, mekanik, hepatik, renal ve psikososyal komplikasyonlarla ilişkili, kronik ve tekrarlayıcı bir hastalıktır. Yaşam tarzı müdahaleleri tedavinin temelini oluşturmaya devam etmekle birlikte, bu yaklaşımların tek başına yeterli yarar sağlamadığı durumlarda farmakoterapi endikedir. Bu durum özellikle beden kütle indeksi 30 kg/m² ve üzerinde olan bireyler ile obeziteyle ilişkili komplikasyonların varlığında beden kitle indeksi 27 kg/m² ve üzerinde olan kişiler için geçerlidir. İnkretin temelli tedaviler, bazı bariatrik cerrahi yöntemlerle elde edilen kilo kaybına yaklaşan veya bunu aşan sonuçlar sağlayarak obezite tedavisinde önemli bir dönüşüm yaratmıştır. Liraglutid, haftada bir uygulanan semaglutid ve tirzepatid kilo kaybı sağlamakta ve kilo azaltıcı etkilerinin ötesinde çeşitli klinik yararlar göstermektedir. Tedavi seçimi; beklenen kilo kaybı, obeziteyle ilişkili komplikasyonlar, tolerabilite, kontrendikasyonlar, uygulama yolu, tedaviye erişim, maliyet ve hasta tercihleri doğrultusunda bireyselleştirilmelidir. Tedavinin kesilmesini sıklıkla yeniden kilo alımı ve metabolik iyileşmelerin gerilemesi izlediğinden, inkretin temelli farmakoterapi uzun süreli, hastalığın seyrini değiştirici bir tedavi olarak değerlendirilmelidir. Güncel kanıtlar, tedavi etkinliğinin zaman içinde vücut ağırlığı, bel çevresi, glisemik kontrol, kardiyovasküler risk faktörleri, fonksiyonel durum ve hasta tarafından bildirilen sonuçlar üzerinden değerlendirildiği, komplikasyon merkezli bir yaklaşımı desteklemektedir.

Anahtar Kelimeler

• Obezite
• inkretin bazlı tedavi
• GLP-1 reseptör agonistleri
• semaglutid
• tirzepatid

Kaynakça

1. 1. Sbraccia P, Dicker D. Obesity is a chronic progressive relapsing disease of particular interest for internal medicine. Intern Emerg Med. 2023;18(1):1-5.
2. 2. Ahmed SK, Mohammed RA. Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metabol Open. 2025;27:100375.
3. 3. Satman I, Yilmaz T, Sengul A, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care. 2002;25(9):1551-1556.
4. 4. Oksuz E, Malhan S, Alis H, et al. Annual Health Expenditures by Body Mass Index Categories and the Economic Impact of Obesity in Turkiye: A Retrospective Modeling Study. Obes Facts. 2025;18(3):269-286.
5. 5. Satman I, Omer B, Tutuncu Y, et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol. 2013;28(2):169-180.
6. 6. Sonmez A, Haymana C, Demirci I, et al. Turkish cross-sectional survEy of glycemic and other Metabolic parameters in patients with type 2 Diabetes in 2023: Comparison with 2018 nationwide data (TEMD-2 study). J Diabetes Complications. 2026;40(9):109348.
7. 7. Nadolsky K, Garvey WT, Agarwal M, et al. American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update. Endocr Pract. 2025;31(11):1351-1394.
8. 8. Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Curr Obes Rep. 2017;6(2):187-194.

9. 9. Bluher M. An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes. Diabetes Obes Metab. 2025;27 Suppl 2(Suppl 2):3-19.
10. 10. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
11. 11. Jensterle M, Rizzo M, Haluzik M, Janez A. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Adv Ther. 2022;39(6):2452-2467.
12. 12. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488.
13. 13. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22.
14. 14. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451.
15. 15. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322.
16. 16. Pedersen SD, Manjoo P, Dash S, Jain A, Pearce N, Poddar M. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. CMAJ. 2025;197(27):E797-E809.
17. 17. Semaglutide for cardiovascular risk reduction in people who are overweight or have obesity without diabetes (new indication). Aust Prescr. 2025;48(3):107-108.
18. 18. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
19. 19. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984.
20. 20. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-1413.
21. 21. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.
22. 22. Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705-719.
23. 23. Wharton S, Freitas P, Hjelmesaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963.
24. 24. Frias JP, Auerbach P, Bajaj HS, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9(9):563-574.
25. 25. Nauck MA, Tuttle KR, Tschop MH, Bluher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407(10531):892-908.
26. 26. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
27. 27. Wilson L, Zhao Z, Divino V, et al. Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER). Diabetes Obes Metab. 2026;28(3):2403-2415.
28. 28. McGowan BM, Bruun JM, Capehorn M, et al. Efficacy and safety of once-weekly semaglutide 2.4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol. 2024;12(9):631-642.
29. 29. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121.
30. 30. Chianetta R, Giannitrapani L, Lipari AG, et al. Emerging Therapeutic Perspectives in Obese Patients with MASLD Leading to Compensated Advanced Chronic Liver Disease. Biomolecules. 2026;16(6):797
31. 31. Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic Treatment of Overweight and Obesity in Adults. In: Feingold KR, Adler RA, Ahmed SF, et al, eds. Endotext. 2000.
32. 32. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022;27(13):4315.
33. 33. Jastreboff AM, Aronne LJ, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. Reply. N Engl J Med. 2022;387(15):1434-1435.
34. 34. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626.
35. 35. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-2918.
36. 36. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
37. 37. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36.
38. 38. Aamir AB, Latif R, Alqoofi JF, et al. Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data. J Clin Med Res. 2025;17(5):285-296.
39. 39. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437.
40. 40. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310.
41. 41. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205.
42. 42. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420.
43. 43. Lam CSP, Rodriguez A, Aminian A, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity (Silver Spring). 2025;33(9):1645-1656.
44. 44. Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1):145.
45. 45. Galli M, Benenati S, Laudani C, et al. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025;86(20):1805-1819.
46. 46. Eldesouki MH, Alkasabrah O, Kloub M, et al. Cohort Study: Risk of Gallstones and Biliary Complications With Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes. United European Gastroenterol J. 2026;14(5):e70238.
47. 47. Nogueira A, Rassi TNO, Iqbal A, et al. Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis. Diabetes Care. 2026;49(5):724-729.
48. 48. Wyckoff JA, Lapolla A, Asias-Dinh BD, et al. Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110(9):2405-2452.
49. 49. Saad Alfaiz A. GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review. Ann Med Surg (Lond). 2025;87(12):8597-8603.
50. 50. McGowan B, Ciudin A, Baker JL, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31(10):3317-3329.
51. 51. West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304.
52. 52. Lempesis IG, Dalamaga M. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. Metabol Open. 2026;30:100463.
53. 53. Sabatella L, Ortega PM, Azcarate VV, et al. Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists: A Network Meta-Analysis of Randomized Controlled Trials. Obesity (Silver Spring). 2026;34(4):770-781.
54. 54. Tan YW, Shang M, Davis S, Gananadha S. GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis. Langenbecks Arch Surg. 2025;410(1):295.